"Sculptra vs filler" and its named versions — Sculptra vs Juvéderm, SKINVIVE vs Sculptra, Radiesse vs Juvéderm, Radiesse vs Voluma — draw about 3,500 US searches a month between them (clickstream estimate, October 2026). Underneath each is the same question: how does a collagen stimulator compare with a hyaluronic-acid filler? This page sets the two classes side by side on what can be checked — what each is, what FDA approved, what randomized trials comparing them found over time, and what happens if something needs undoing — as of 11 October 2026. It is not a recommendation for either. The Sculptra–Radiesse question, two stimulators against each other, has its own page.
The two classes at a glance
| Sculptra (a stimulator) | Hyaluronic-acid filler (Juvéderm family, Restylane and others) | |
|---|---|---|
| Material | poly-L-lactic acid (PLLA), a synthetic polymer | cross-linked hyaluronic acid, a sugar chain the skin also makes |
| Supplied as | powder, mixed with sterile water before use | ready-to-inject gel in a syringe |
| When the change shows | gradually, over months and several sessions | on the day of injection |
| Can it be dissolved? | no | yes, with hyaluronidase (an off-label use) |
| Contains collagen? | no | no |
Neither class contains collagen. Sculptra is called a collagen stimulator because its effect is credited to the tissue response around the particles; how that claim was measured is in our Sculptra explainer, and the older fillers that really were collagen are covered in collagen injections.
What FDA approved, dated
| Date | Product | What FDA approved |
|---|---|---|
| 3 Aug 2004 | Sculptra | facial fat loss in people with HIV |
| 2 Jun 2006 | Juvéderm 24HV, 30, 30HV (P050047) | moderate to severe facial wrinkles and folds, such as nasolabial folds |
| 28 Jul 2009 | Sculptra | nasolabial folds and other facial wrinkles |
| 22 Oct 2013 | Juvéderm Voluma XC (P110033) | cheek augmentation for age-related midface volume loss |
| 12 Jun 2020 | Juvéderm Voluma XC | chin augmentation added |
| 11 May 2023 | SKINVIVE by Juvéderm (P110033/S059) | injection into the skin to improve cheek skin smoothness |
| 2023 | Sculptra | cheek wrinkles |
| 11 Jun 2026 | SKINVIVE (P110033/S099) | neck lines added |
The labels describe different jobs. Voluma is placed deep to add volume to the cheek or chin; SKINVIVE is placed in the skin to change its surface; Sculptra's approvals are for folds, wrinkles and HIV-related fat loss. "SKINVIVE vs Sculptra" compares two products approved for different things, which our reading of the SKINVIVE approval file sets out from the hyaluronic-acid side.
What the head-to-head trials found
A PubMed search on 11 October 2026 for poly-L-lactic acid and hyaluronic-acid fillers together returned 169 records; restricted to randomized designs, 9, of which four are randomized trials comparing a PLLA filler with an HA filler:
| Trial | Design | Early result | Later result |
|---|---|---|---|
| Hyun 2015 | Korea; nasolabial folds; evaluator-blinded | — | 24 weeks: mean improvement 2.09 grades with PLLA vs 1.54 with HA; PLLA judged non-inferior |
| Zhang 2025 | China; 331 people; midface volume; assessor-blinded | 6 months: 93.0% vs 69.3% effective (midface scale) | 12 months: 84.9% vs 47.0%; more injection-site reactions with PLLA, resolving in 1–3 days |
| Wang 2026 | China; 252 people, 8 centres; nasolabial folds; double-blind | HA ahead at week 4 | 48 weeks: 92.4% vs 59.3% effective correction; PLLA needed more early sessions |
| Liu 2026 | China; 208 randomized, 6 centres; nasolabial folds | similar at 4 weeks (89.8% vs 92.8%) and 12 weeks | 120 weeks: 55.6% (35/63) vs 25.0% (18/72) |
The pattern is consistent: where the first weeks were measured, hyaluronic acid matched or beat PLLA, and in all four trials PLLA led from six months onward. Three limits bind it. None of the four tested Sculptra — each used another poly-L-lactic acid product, so the results describe the material, not the brand. The comparators were particular HA fillers, not Juvéderm or Voluma specifically. And the 120-week figures come from an observational extension that kept 135 of the 208 people randomized, which the authors themselves say must be read "in light of attrition". Sculptra's own approval trials compared it with collagen and with no treatment, not with a hyaluronic-acid filler.
The difference that matters when something goes wrong
A hyaluronic-acid filler can be broken down with hyaluronidase, an enzyme, which is why HA is described as reversible. Poly-L-lactic acid is not hyaluronic acid, and no dissolving agent exists for Sculptra; nodules or misplaced product are managed in other ways and the material is left for the body to break down.
Reversibility has a qualification of its own. The current US label for Hylenex, a recombinant hyaluronidase (label dated November 2024, read 11 October 2026), lists three indications — subcutaneous hydration, increasing the dispersion of other injected drugs, and subcutaneous urography. Dissolving filler is not one of them, so even the reversal of an HA filler is an off-label use of a drug.
FDA device reports
On 11 October 2026, FDA's MAUDE database held:
| Brand name searched | Reports |
|---|---|
| Juvéderm (all products) | 9,894 |
| Voluma | 4,152 |
| Sculptra | 2,023 |
| Restylane | 1,224 |
| SKINVIVE | 376 |
These are counts, not rates. The number of treatments behind each brand is not public, a Juvéderm-family product may be named under either search, reporting is voluntary for patients and clinicians, and one event can be filed more than once. The counts say where reports exist, not which product is riskier; our Sculptra explainer covers what its own reports describe.
What is and is not established
Established: Sculptra and hyaluronic-acid fillers are different materials with different approved uses; in the randomized trials that compared the classes, HA worked faster and PLLA lasted longer; hyaluronic acid can be broken down with hyaluronidase and PLLA cannot; neither contains collagen.
Not established: how Sculptra itself compares with Juvéderm, Voluma or SKINVIVE, since no randomized trial has compared those products directly; whether either class carries the lower complication rate per treatment; and which is right for any one face. Those are questions for a board-certified clinician who can explain their own experience with both.
Sources
- US FDA, Premarket Approval database via openFDA
device/pma, queried 2026-10-11:P050047(Juvéderm, original approval 2006-06-02);P110033(Juvéderm Voluma XC 2013-10-22; S047 chin 2020-06-12; S059 SKINVIVE 2023-05-11; S099 SKINVIVE neck lines 2026-06-11);P030050(Sculptra; dates as given on our Sculptra pages). - US FDA, MAUDE via openFDA
device/event, queried 2026-10-11:device.brand_name= juvederm (9,894), voluma (4,152), sculptra (2,023), restylane (1,224), skinvive (376). - Hylenex recombinant (hyaluronidase human injection) prescribing information, Indications and Usage, label effective 2024-11-11, via openFDA
drug/label, read 2026-10-11. - Hyun MY, Lee Y, No YA, et al. Efficacy and safety of injection with poly-L-lactic acid compared with hyaluronic acid for correction of nasolabial fold: a randomized, evaluator-blinded, comparative study. Clin Exp Dermatol 2015;40(2):129-35. PMID 25319932.
- Zhang Y, Zhang X, Gao X, et al. Efficacy and safety of poly-L-lactic acid for correction of midfacial volume loss and contour defects: a prospective, multicenter, randomized, parallel-controlled, evaluator-blinded, superiority trial. J Cosmet Dermatol 2025;24(7):e70230. PMID 40679154.
- Wang Z, Ting W, Zhao H, et al. Long-term correction of nasolabial folds using poly-L-lactic acid microspheres: a multicenter, double-blinded, randomized trial. Aesthet Surg J Open Forum 2026;8:ojag001. PMID 41694326.
- Liu Y, Zhang G, Yang F, et al. Divergent time courses of poly-L-lactic acid and hyaluronic acid fillers for nasolabial fold correction: a multicenter randomized trial with 120-week follow-up. J Craniofac Surg 2026 (online ahead of print). PMID 42594306.
- PubMed E-utilities searches, 2026-10-11:
("poly-L-lactic"[tiab] OR PLLA[tiab] OR sculptra[tiab]) AND ("hyaluronic acid"[tiab] OR juvederm[tiab] OR restylane[tiab] OR voluma[tiab]) AND (filler*[tiab] OR injection*[tiab])(169); with a randomized filter (9, titles read; four are PLLA-vs-HA randomized trials).